Cancer care and cancer survivorship care in the United States: Will we be able to care for these patients in the future? Journal Article


Authors: Shulman, L. N.; Jacobs, L. A.; Greenfield, S.; Jones, B.; McCabe, M. S.; Syrjala, K.; Diller, L.; Shapiro, C. L.; Marcus, A. C.; Campbell, M.; Santacroce, S.; Kagawa-Singer, M.; Ganz, P. A.
Article Title: Cancer care and cancer survivorship care in the United States: Will we be able to care for these patients in the future?
Abstract: Studies have predicted a shortfall in the workforces of oncologists and primary care physicians in the coming years. These estimates are based on the number of current physicians, those leaving the profession, and the rate of new physicians joining each profession, as benchmarked against the number of patients needing care. For active cancer treatment, and particularly for the care of cancer survivors, it is likely that current calculations underestimate the shortfalls which will occur in the next 5 to 10 years. Ever more complex cancer therapies are leading to better outcomes with improved cure rates and prolonged survivals even for patients who ultimately succumb to their disease, resulting in a substantial increase in utilization of health care resources. Due to these factors, utilization of health care resources by cancer patients and cancer survivors is climbing at a rate greater than would be predicted by patient numbers alone. The combination of an increased number of patients utilizing more resources calls into question the ability of our healthcare system to meet the needs of cancer patients and cancer survivors in the future. It is crucial that innovative models of care (utilizing nonphysician providers) be developed and evaluated to assure quality care and services for this growing population. Copyright © 2009 by American Society of Clinical Oncology.
Keywords: cancer chemotherapy; cancer survival; treatment outcome; bevacizumab; fluorouracil; unspecified side effect; united states; cancer patient; follow up; gene overexpression; metastasis; breast cancer; heart disease; epidermal growth factor receptor 2; oncology; cetuximab; cancer therapy; irinotecan; health care quality; health care utilization; health service; patient care; colon cancer; health care system; trastuzumab; oxaliplatin; primary medical care; phosphotransferase inhibitor; oncogene neu; health care need
Journal Title: Journal of Oncology Practice
Volume: 5
Issue: 3
ISSN: 1554-7477
Publisher: American Society of Clinical Oncology  
Date Published: 2009-05-01
Start Page: 119
End Page: 123
Language: English
DOI: 10.1200/jop.0932001
PROVIDER: scopus
PMCID: PMC2790692
PUBMED: 20856750
DOI/URL:
Notes: --- - "Cited By (since 1996): 13" - "Export Date: 28 June 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mary McCabe
    108 McCabe